ST Innovative Diagnostics

Developing a multi-cancer early detection, screening & monitoring solution based on a proprietary blood test.

Health Tech & Life Sciences
Active
Seed Be'er Ya'akov, Israel Founded 2022
Last updated 2026-07-20
Total raised
Last: Undisclosed Round 2024-07
Stage
Seed
Founded
2022
Headcount
5
HQ
Be'er Ya'akov, Israel
Sector
Health Tech & Life Sciences

About

ST Innovative Diagnostics (ST Diagnostics) is an Israeli startup focused on developing a non-invasive, real-time blood test for the early detection and monitoring of various malignancies. The company's breakthrough technology is based on Fibrinogen Like Protein 2 (FGL2) activity in platelets, showing high accuracy, sensitivity, and specificity in clinical studies for Lymphoma, Lung-Cancer, Colon & Prostate Cancers, and Cutaneous T-Cell Lymphoma. The company aims to create a comprehensive FGL2 baseline profiling database using AI to develop a predictive model for routine cancer screening. Their product, LymFollow, is an innovative diagnostic kit for monitoring treatment response and relapse prediction in aggressive Non-Hodgkin's Lymphoma patients. The company holds 7 patents across the US, Europe, China, Hong Kong, and Israel.

Funding history · 1 round · — total

2024-06
Undisclosed Round Undisclosed

Q&A

What is ST Innovative Diagnostics' primary focus?
ST Innovative Diagnostics focuses on developing a novel blood-based test for monitoring malignancies and predicting relapse across various cancers.
What is the core technology behind ST Innovative Diagnostics' test?
The company's proprietary technology measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring.
What clinical evidence supports ST Innovative Diagnostics' technology?
Proof-of-concept clinical studies have shown a high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma.
What are the potential future applications for ST Innovative Diagnostics' technology?
The technology shows promise for early detection of treatment resistance in NHL patients and is planned to expand to solid tumor monitoring and diagnosis, including Metastatic Colorectal and Pancreatic Cancers.
When was ST Innovative Diagnostics founded?
ST Innovative Diagnostics was founded in July 2022.
What is ST Innovative Diagnostics' current employee count?
ST Innovative Diagnostics has 1-10 employees.
What is the total funding raised by ST Innovative Diagnostics to date?
As of July 2024, ST Innovative Diagnostics has raised a total of $70,000.
Who is the Chief Science Officer at ST Innovative Diagnostics?
Esther Rabizadeh is the Chief Science Officer at ST Innovative Diagnostics.

Team · 1

Dr. Esther Rabizadeh
Founder · CSO & Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsMoleculesCells
Target customers
Healthcare & Life SciencesMedical Devices IndustryMedical EquipmentHealthcarePatientsLaboratoriesInsurance CompaniesProviders
Business model
B2BB2B2C

Highlights

1 PatentsVerified

Tags

cancer-diagnosticsmedical-devicesdiagnosticsearly-detectiondetectionnon-invasivecancerproteinslife-sciences
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitest-diagnostic.com
LinkedInlinkedin.com/company/103237856

Identifiers & details

Legal nameST Innovative Diagnostics Ltd.
Founded2022-7
Employees (exact)5

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domainst-diagnostic.com

Certificate / subdomain footprint

Subdomains1

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516655594
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2022-07-28
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Active charges / liens0
Registry events0
Registered addressסמ האנקור 12 באר יעקב